Holen Sie sich die Stockscreener-App
0.4876
1.57%
0.00755
Schlusskurs vom Vortag:
$0.48
Offen:
$0.48
24-Stunden-Volumen:
15,387
Relative Volume:
0.51
Marktkapitalisierung:
$2.20M
Einnahmen:
$7,500
Nettoeinkommen (Verlust:
$-9.83M
KGV:
-0.0797
EPS:
-6.1164
Netto-Cashflow:
$-9.33M
1W Leistung:
-0.05%
1M Leistung:
-3.67%
6M Leistung:
-13.29%
1J Leistung:
-63.89%
1-Tages-Spanne:
$0.48
$0.50
1-Wochen-Bereich:
$0.4605
$0.5189
52-Wochen-Spanne:
$0.4605
$1.45
Oragenics Inc Stock (OGEN) Company Profile
Firmenname
Oragenics Inc
Sektor
Branche
Telefon
813-286-7900
Adresse
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Compare OGEN vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
0.4876 | 2.20M | 7,500 | -9.83M | -9.33M | -6.1164 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oragenics Inc Aktie (OGEN) Neueste Nachrichten
Oragenics Highlights Nasal Innovation at Industry Forum - TipRanks
Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum - GlobeNewswire
Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update - manilatimes.net
Oragenics Faces Potential NYSE American Delisting on Equity Shortfall - minichart.com.sg
Oragenics Faces NYSE Compliance Challenges Amid Trial Progress - TipRanks
Oragenics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Oragenics (NYSE: OGEN) faces NYSE listing warning as equity falls short - Stock Titan
Oragenics Updates Phase IIa Trial Progress, FDA Regulatory Pathway and NYSE American Listing Status - Quiver Quantitative
Oragenics (OGEN) Earnings Report: EPS Exceeds Its Estimate for the Current Session; Trading Response - careplusvn.com
Oragenics (OGEN) Slips to $0.53, Holding Key Support Despite 1.16% DeclineRange Breakout - vinanet.vn
Oragenics: Q2 Earnings Snapshot - AOL.com
Oragenics (OGEN) flags going concern risk with $4.7M loss and $3.9M cash - Stock Titan
Oragenics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Oragenics (OGEN) Gains 2% as Micro-Cap Biotech Holds Key Support at $0.47Collar Trade - dars.gov.et
OGEN Q2 2023 Earnings: Narrower EPS Beat Lifts Shares 2.0%Earnings Beat Streak - careplusvn.com
Oragenics Q2 2023 Earnings: Narrowed Loss Surprises as Operational Efficiency ImprovesEarnings Acceleration Picks - careplusvn.com
Oragenics Inc. Revenue Breakdown – AMEX:OGEN - TradingView
Oragenics Inc (OGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oragenics Inc (OGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oragenics Inc (OGEN) Cash Flow - TradingKey
OGEN|Oragenics Inc|Price:0.507|Chg%:-0.004 - TradingKey
TradingKey - TradingKey
Oragenics Inc (OGEN) Valuation: PE, PB & Fair Value Analysis - tradingkey.com
OGEN Q2 2023 Earnings: EPS Surprises to the Upside Despite No RevenueOperating Income Trends - dars.gov.et
OGEN Q2 2023 Earnings: EPS Beat on 50.65% Surprise but No Revenue; Stock DeclinesFull Year Guidance - dars.gov.et
OGEN Q2 2023 Earnings: EPS Beats Estimates by 50.65% Despite No Revenue, Stock DeclinesOperating Income Trends - dars.gov.et
Oragenics Inc. (OGEN) Holds Near Support Amid Modest DeclineBPI Bear Correction - dars.gov.et
OGEN Q2 2023 Earnings: EPS Surprise Beats Estimates Despite Stock DeclineGuidance vs Actual - vinanet.vn
Oragenics Incto Receive Exclusive License - Moomoo
Form 4 Oragenics Inc For: 7 July By Investing.com - Investing.com Nigeria
Oragenics (OGEN) CFO receives 55,900 stock options at $0.59 exercise price - Stock Titan
ORAGENICS (OGEN) CFO reports initial holdings, including 10,000-share stock option grant - Stock Titan
Oragenics Activates All Australian Phase IIa Trial Sites for Concussion Drug ONP-002 - citybuzz -
Oragenics Achieves Full Activation of Australian Phase IIa Trial NetworkAll Three Sites Now Enrolling - The Manila Times
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling - GlobeNewswire
Oragenics Appoints New Chief Financial Officer and Leader - TipRanks
Oragenics, Inc. Announces Appointment of John Spencer to Chief Financial Officer, Effective July 1, 2026 - marketscreener.com
OGEN Q2 2023 Earnings: EPS Beat Driven by Cost Control Amid Ongoing Clinical DevelopmentEarnings Forecast Report - dars.gov.et
Price to earnings forward of Oragenics Inc. – AMEX:OGEN - TradingView
OGEN Q2 2023 Earnings: Narrowed Loss Surpasses Estimates, Stock Declines Amid No RevenueEarnings Quality Analysis - DonanımHaber
OGEN Q2 2023 Earnings: Narrower-Than-Expected Loss as Shares Drift LowerAnalyst Consensus Shift - po-news-eg.net
Price to book forward of Oragenics Inc. – AMEX:OGEN - TradingView
Enterprise value to EBIT forward of Oragenics Inc. – AMEX:OGEN - TradingView
Enterprise value to revenue forward of Oragenics Inc. – AMEX:OGEN - TradingView
OGEN Q2 2023 Earnings: Significant EPS Beat Amidst No Revenue ReportedTrough Earnings Signal - dars.gov.et
Oragenics Inc (OGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Oragenics, Inc. Actuals & Estimates (AMEX:OGEN) - TradingView
Oragenics (OGEN) Sees Minor Pullback as Biotech Stock Holds Above Key SupportMA Cross Alert - dars.gov.et
OGEN Q2 2023 Earnings: EPS Beat as Operating Loss NarrowsPretax Income Report - po-news-eg.net
Oragenics Inc (OGEN) Institutional Confidence - TradingKey
Oragenics Inc. (OGEN) Holds Near $0.59 Support Amid Low Volatility – Key Levels in FocusEquity Put Call - dars.gov.et
Finanzdaten der Oragenics Inc-Aktie (OGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):